NMN (Nikotinamid mononukleotid) analysis

The NMN Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of nicotinamide mononucleotide (NMN) in oral dosage forms and raw active pharmaceutical ingredient (API) powders.

The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m).

About NMN

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and an intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). NMN is converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNATs).

NAD+ is an essential cellular coenzyme involved in energy metabolism, redox reactions, and numerous enzymatic processes. NMN has therefore been studied as an NAD+ precursor in both preclinical and clinical research.

Key Features

• Targeted identification and quantification of NMN
• Suitable for pills, tablets, capsules, and raw API powders
• Analysis by HPLC
• Results for oral products reported in mg per tablet or capsule
• Purity reporting in % (m/m) for raw API powders
• Minimum sample amount of three tablets or capsules
• Minimum sample amount of 200 mg for raw API powders
• Average turnaround time of 7 business days

Analysis Parameters

• Target compound: Nicotinamide mononucleotide
• Other name: NMN
• CAS number: 1094-61-7
• Testing method: HPLC
• Result format for oral products: mg per tablet or capsule
• Result format for raw API powders: Purity in % (m/m)
• Minimum sample amount for oral products: Three tablets or capsules
• Minimum sample amount for raw API powders: 200 mg
• Average turnaround time: 7 business days

Important Notice

• NMN is not a peptide. Peptide purity is therefore not measured as part of this analysis.
• This analysis is specifically intended for NMN. It does not automatically screen the sample for related compounds, degradation products, contaminants, or undeclared substances.
• Purity reporting in % (m/m) is available only for raw API powders.

Optional Additional Analyses

The following optional laboratory services are available:

• Complete Raw Analytical Data
• Alternative Result Format: Purity in % (m/m) – only for raw API powders
• Batch Variance Testing
• Fentanyl Screening
• LCMS Screening For Peptide Contamination
• Heavy Metals Analysis (As, Cd, Pb, Hg)
• Additional Laboratory Report